Agenus to present 3-year survival data for botensilimab-balstilimab ovarian cancer study at IGCS 2026
AGEN•IGCS presentation planned for ovarian cancer data
Agenus will present three-year overall survival data for botensilimab with balstilimab in recurrent ovarian cancer at IGCS 2026.
The poster will cover outcomes from the Phase 1b C-800-01 study cohort, including platinum-refractory or platinum-resistant patients.
Results will be analyzed by platinum sensitivity status, aiming to clarify durability of benefit in hard-to-treat disease.
Presentation is scheduled for Oct. 3, 2026, at the IGCS Annual Global Meeting in Montreal.
